BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

BioCryst (Nasdaq: BCRX) announced that its compensation committee granted a newly hired employee 18,300 restricted stock units (RSUs) as inducement equity under Nasdaq Listing Rule 5635(c)(4).

The RSUs were granted effective January 2, 2026, vest in four equal annual installments beginning on the one-year anniversary of the grant date, and are subject to the recipient’s continued service and the terms of BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement.

News Market Reaction – BCRX

+2.29%

1 alert

+2.29% News Effect

On the day this news was published, BCRX gained 2.29%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

RSU grant size: 18,300 shares Vesting schedule: 4 annual installments

2 metrics

RSU grant size 18,300 shares Inducement RSUs to one newly hired employee effective Jan 2, 2026

Vesting schedule 4 annual installments RSUs vest in four equal annual installments from first anniversary

Market Reality Check

Price: $9.53 Vol: Volume 4,407,346 vs 20-da...

normal vol

$9.53 Last Close

Volume Volume 4,407,346 vs 20-day average 3,402,443 (relative volume 1.3x). normal

Technical Price $7.41 is trading below the 200-day MA of $8.25 and 34.48% under its 52-week high.

Peers on Argus

BCRX was down 1.2% while peers were mixed: HROW up 6.86%, PAHC up 3.2%, AMPH up ...

BCRX was down 1.2% while peers were mixed: HROW up 6.86%, PAHC up 3.2%, AMPH up 1.95%, AVDL roughly flat and BGM down 3.06%, indicating stock-specific rather than sector-driven pressure.

Historical Context

5 past events · Latest: Dec 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 12	FDA approval	Positive	-0.1%	ORLADEYO oral pellets FDA approval for pediatric HAE prophylaxis.
Dec 04	Inducement grants	Neutral	+0.1%	Inducement stock options and RSUs for four new hires.
Dec 03	Acquisition step	Positive	+9.6%	Early termination of HSR waiting period for Astria acquisition.
Nov 12	Partner earnings	Neutral	-0.7%	Astria Q3 2025 financials and details of BCRX acquisition terms.
Nov 06	Clinical data	Positive	-1.9%	New APeX-P pediatric ORLADEYO data and burden-of-illness findings.

Pattern Detected

Recent history shows several positive regulatory and clinical milestones where the stock reaction was flat or negative, suggesting a tendency to underreact or fade good news.

Recent Company History

Over the last few months, BCRX reported multiple catalysts, including an FDA approval of ORLADEYO oral pellets for pediatric HAE on Dec 12, 2025, and early termination of the HSR waiting period for the Astria acquisition on Dec 3, 2025. It also issued repeated inducement equity grants under its Inducement Equity Incentive Plan, clinical data updates, and Astria’s earnings and clinical results. Price reactions were often modest and sometimes negative even on positive news, framing today’s small, routine hiring-related RSU grant within an ongoing stream of operational updates.

Market Pulse Summary

This announcement details a standard inducement grant of 18,300 restricted stock units to a newly hi...

Analysis

This announcement details a standard inducement grant of 18,300 restricted stock units to a newly hired employee under Nasdaq Listing Rule 5635(c)(4), vesting in four equal annual installments. It follows a series of recent regulatory, clinical, and M&A developments, including pediatric ORLADEYO approval and progress on the Astria acquisition. Investors may focus more on execution of these larger initiatives while monitoring ongoing equity-based compensation and insider activity.

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4), inducement equity incentive plan

3 terms

restricted stock units financial

"granted one newly-hired employee restricted stock units (RSUs) covering an"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement equity incentive plan financial

"subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan"

An inducement equity incentive plan is a program that grants employees or executives company shares or stock options to motivate and reward their work, often as a way to attract new talent. It aligns their interests with the company's success, encouraging them to contribute to long-term growth. For investors, such plans can influence a company's stock performance and overall financial health by motivating key personnel.

AI-generated analysis. Not financial advice.

RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted one newly-hired employee restricted stock units (RSUs) covering an aggregate of 18,300 shares of BioCryst common stock. The RSUs were granted as of January 2, 2026, as inducements material to such employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. The RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant.

About BioCryst Pharmaceuticals
BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (“HAE”) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:
Investors:
investorrelations@biocryst.com

Media:
media@biocryst.com

FAQ

What did BioCryst (BCRX) announce on January 6, 2026 about inducement grants?

BioCryst announced a grant of 18,300 RSUs to a newly hired employee, effective January 2, 2026, under Nasdaq Listing Rule 5635(c)(4).

How do the 18,300 RSUs for BioCryst (BCRX) vest and when do they start vesting?

The RSUs vest in four equal annual installments starting on the one-year anniversary of the January 2, 2026 grant date, subject to continued service.

What rule did BioCryst (BCRX) cite for the inducement RSU grant?

The grant was made in accordance with Nasdaq Listing Rule 5635(c)(4), which covers inducement awards for newly hired employees.

Are BioCryst's inducement RSUs governed by a plan or agreement?

Yes. The RSUs are subject to BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant.

Does the BioCryst (BCRX) announcement state any cash or earnings impact from the 18,300 RSU grant?

No. The announcement describes the RSU grant, vesting schedule, and plan terms but does not disclose cash cost or earnings impact.